Literature DB >> 1551494

Prognostically significant heterogeneity of cytoplasmic islet cell antibodies in relatives of patients with type I diabetes.

R Gianani1, A Pugliese, S Bonner-Weir, A J Shiffrin, J S Soeldner, H Erlich, Z Awdeh, C A Alper, R A Jackson, G S Eisenbarth.   

Abstract

A significant proportion of relatives of patients with insulin-dependent (type I) diabetes with high titers of cytoplasmic islet cell autoantibodies (ICAs) do not progress to overt diabetes with up to 8 yr of follow-up. This may reflect that follow-up of such relatives has not been long enough to observe diabetes, that despite expression of identical ICAs, some relatives will not progress to diabetes; or that there is heterogeneity in what is identified as ICA. We identified a subset of ICA that was restricted in its species (not reacting with mouse islets) and cell-type reactivity within islets (beta-cell specific). Only one of eight relatives whose sera had the restricted pattern of reactivity progressed to overt diabetes, and on sequential evaluation, all but the one relative who progressed to diabetes have maintained normal first-phase insulin secretion to intravenous glucose. In contrast, by life-table analysis, 70% of relatives expressing nonrestricted ICA became diabetic within 5 yr of follow-up (1 of 8 vs. 16 of 25 diabetic at last follow-up, P less than 0.02). Moreover, preliminary data suggest a significant association of the human leukocyte antigen DQB1*0602 allele of DR2 haplotypes with the restricted ICA pattern (4 of 5 DQB1*0602 restricted vs. 0 nonrestricted ICA, P = 0.006). We propose that expression of a genetically determined restricted ICA pattern confers a markedly lower risk for progression to diabetes.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1551494     DOI: 10.2337/diab.41.3.347

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  27 in total

Review 1.  Prediction and prevention of type I diabetes.

Authors:  R Gianani; G S Eisenbarth
Journal:  J Endocrinol Invest       Date:  1994 Jul-Aug       Impact factor: 4.256

Review 2.  Superantigens in insulin-dependent diabetes mellitus.

Authors:  P Luppi; M Trucco
Journal:  Springer Semin Immunopathol       Date:  1996

Review 3.  Strategies for preventing type I diabetes mellitus.

Authors:  C F Verge; G S Eisenbarth
Journal:  West J Med       Date:  1996-03

4.  Baclofen, a gamma-aminobutyric acid-b receptor agonist, delays diabetes onset in the non-obese diabetic mouse.

Authors:  P E Beales; M Hawa; A J Williams; M C Albertini; A Giorgini; P Pozzilli
Journal:  Acta Diabetol       Date:  1995-03       Impact factor: 4.280

5.  Islet cell autoantigen 69 kD (ICA69). Molecular cloning and characterization of a novel diabetes-associated autoantigen.

Authors:  M Pietropaolo; L Castaño; S Babu; R Buelow; Y L Kuo; S Martin; A Martin; A C Powers; M Prochazka; J Naggert
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

6.  Quantification of human cytoplasmic islet-cell antibodies which cross-react with mouse pancreas: a follow-up study in type 1 (insulin-dependent) diabetic patients and in first-degree relatives.

Authors:  P Saï; A Elmansour; M Audrain; B Charbonnel; S Bardet
Journal:  Diabetologia       Date:  1993-08       Impact factor: 10.122

7.  Two subsets of HLA-DQA1 alleles mark phenotypic variation in levels of insulin autoantibodies in first degree relatives at risk for insulin-dependent diabetes.

Authors:  A Pugliese; T Bugawan; R Moromisato; Z L Awdeh; C A Alper; R A Jackson; H A Erlich; G S Eisenbarth
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

8.  Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity.

Authors:  E Bonifacio; S Genovese; S Braghi; E Bazzigaluppi; V Lampasona; P J Bingley; L Rogge; M R Pastore; E Bognetti; G F Bottazzo
Journal:  Diabetologia       Date:  1995-07       Impact factor: 10.122

9.  Human monoclonal islet specific autoantibodies share features of islet cell and 64 kDa antibodies.

Authors:  W Richter; T H Eiermann; J Endl; J Seissler; S Wolfahrt; M Brandt; H Jungfer; W A Scherbaum
Journal:  Diabetologia       Date:  1993-08       Impact factor: 10.122

10.  Islet cell antibody heterogeneity among type 1 (insulin-dependent) diabetic patients.

Authors:  J Timsit; S Caillat-Zucman; H Blondel; P Chédin; J F Bach; C Boitard
Journal:  Diabetologia       Date:  1992-08       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.